Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00705_DB08920_nanopub.RAryA1mG7vkClFktMnpIBTxb4mjXY288u1GLgvJhBZm6Q#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00705_DB08920 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00705_DB08920 label "DDI between Delavirdine and Zuclopenthixol decanoate - Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed. [drugbank_resource:DB00705_DB08920]" assertion.
- drugbank_resource:DB00705_DB08920 identifier "drugbank_resource:DB00705_DB08920" assertion.
- drugbank_resource:DB00705_DB08920 title "DDI between Delavirdine and Zuclopenthixol decanoate - Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed." assertion.
- drugbank:DB00705 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00705_DB08920 assertion.
- drugbank:DB08920 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00705_DB08920 assertion.